Related Experiment Video
Updated: Jul 11, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor
Alberto Radaelli1, Claudia Loardi, Maria Cazzaniga
1Divisione di Riabilitazione Cardiologica - Ospedale San Gerardo, Via Pergolesi, 33, 20052 Monza, Italy.
Insights
High-dose statins and ACE-inhibitors significantly reduce the inflammatory response after coronary artery bypass graft (CABG) surgery. This early treatment with high doses of these cardiovascular drugs almost completely prevents the intense systemic inflammation associated with CABG.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- On-pump coronary artery bypass graft (CABG) surgery can trigger an inflammatory response (IR) that may impair revascularization.
- Understanding the temporal profile of this IR and potential pharmaceutical interventions is crucial for improving patient outcomes.
Purpose of the Study:
- To characterize the temporal profile of the inflammatory response during CABG surgery by measuring markers in systemic and coronary blood.
- To determine if cardiovascular drugs with anti-inflammatory properties, specifically statins and ACE-inhibitors (ACEI), can inhibit this response and at which doses.
Main Methods:
- A randomized study involving 22 patients scheduled for CABG, assigned to standard-dose (STD) or high-dose (HiDo) statin/ACEI combination therapy.
- Serial plasma assays (IL-6, TNF-alpha, E-selectin, vWF, sVCAM-1) from arterial, venous, and coronary sinus blood before, during, and after CABG.
- Myocardial perfusion scans before and 2 months post-surgery.
Main Results:
- Standard-dose (STD) treatment showed significant increases in IL-6 and TNF-alpha post-surgery, irrespective of blood sampling site.
- High-dose (HiDo) treatment drastically attenuated these inflammatory marker increases.
- Myocardial ischemia scores normalized post-CABG in the HiDo group, but not in the STD group.
Conclusions:
- On-pump CABG surgery induces a substantial systemic inflammatory response.
- Early treatment with high doses of ACE-inhibitors and statins can almost completely prevent this inflammatory response.
- High-dose cardiovascular drug therapy appears to improve myocardial revascularization post-CABG.
Background:
On-pump coronary artery bypass graft (CABG) surgery triggers an inflammatory response (IR) which may impair revascularization. The study aimed at (1) characterizing the temporal profile of the IR by assaying appropriate markers in both systemic and coronary blood, and (2) determining whether (and which doses of) cardiovascular drugs known to have antiinflammatory properties, namely statins and ACE-inhibitors (ACEI), inhibit the response.
Methods And Results:
Patients scheduled for CABG (n=22) were randomized to statin/ACEI combination treatment at standard doses (STD, ramipril 2.5/simvastatin 20 mg, or atorvastatin 10 mg), or at high doses (HiDo, ramipril 10 mg, or enalapril 20 mg/simvastatin 80 mg, or atorvastatin 40 mg). Plasma levels of interleukin 6, tumor necrosis factor alpha, E-selectin, von Willebrand factor (vWF), and sVCAM-1 were serially assayed (ELISA) before, during, and after CABG. Blood was drawn from an artery, a systemic vein, and the coronary sinus. Myocardial perfusion scans were obtained before and 2 months after surgery in 19 out of 22 subjects. In the STD group both IL-6 and TNF displayed striking increases which were similar at all sites and peaked 10 to 60 minutes after aortic declamping. Such increases were drastically attenuated in the HiDo group. Instead, only modest increases in venous E-selectin, vWF, and sVCAM-1 were observed. Scintigraphic ischemia scores were entirely normalized after versus before CABG in the HiDo but not in the STD treatment group.
Conclusions:
On-pump CABG surgery is associated with an intense systemic inflammatory response, which can be almost completely prevented by early treatment with high (but not standard) doses of ACE-inhibitors and statins.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies